Cancer Gene Therapy - Table of Contents alert Volume 19 Issue 12

TABLE OF CONTENTS Volume 19, Issue 12 (December 2012) In this issue Reviews Original Articles Also new AOP Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement TakeTake a look at this recent article in The EMBO Journal: The authors’ findings indicate that SUMO modification plays a crucial role in the control of hnRNP-K’s function as a p53 co-activator in response to DNA damage by UV. SUMOylation of hnRNP-K is required for p53-mediated cell-cycle arrest in response to DNA damage Seong Won Lee, Chin Ha Chung et al   Reviews Top Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma J Doukas and A Rolland Cancer Gene Ther 2012 19: 811-817; advance online publication, October 5, 2012; 10.1038/cgt.2012.69 Abstract | Full Text Will T-cell therapy for cancer ever be a standard of care? M K Brenner Cancer Gene Ther 2012 19: 818-821; advance online publication, October 12, 2012; 10.1038/cgt.2012.74 Abstract | Full Text Original Articles Top Delivery of interferons and siRNA targeting STAT3 using lentiviral vectors suppresses the growth of murine melanoma X Wang, P Liu, H Liu, W Yang, Z Liu, Z Zhuo and Y Gao Cancer Gene Ther 2012 19: 822-827; advance online publication, September 28, 2012; 10.1038/cgt.2012.65 Abstract | Full Text Modifications to the INSM1 promoter to preserve specificity and activity for use in adenoviral gene therapy of neuroendocrine carcinomas V Akerstrom, C Chen, M S Lan and M B Breslin Cancer Gene Ther 2012 19: 828-838; advance online publication, October 19, 2012; 10.1038/cgt.2012.66 Abstract | Full Text A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer M A Trujillo, M J Oneal, S McDonough, R Qin and J C Morris Cancer Gene Ther 2012 19: 839-844; advance online publication, October 5, 2012; 10.1038/cgt.2012.68 Abstract | Full Text Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells H Lin, Y Zhang, H Wang, D Xu, X Meng, Y Shao, C Lin, Y Ye, H Qian and S Wang Cancer Gene Ther 2012 19: 845-851; advance online publication, October 5, 2012; 10.1038/cgt.2012.70 Abstract | Full Text Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up L M E Finocchiaro and G C Glikin Cancer Gene Ther 2012 19: 852-861; advance online publication, October 12, 2012; 10.1038/cgt.2012.72 Abstract | Full Text Gene therapy of pancreatic cancer targeting the K-Ras oncogene V Lisiansky, I Naumov, S Shapira, D Kazanov, A Starr, N Arber and S Kraus Cancer Gene Ther 2012 19: 862-869; advance online publication, October 26, 2012; 10.1038/cgt.2012.73 Abstract | Full Text Increased invasion of malignant gliomas after 15-LO-1 and HSV-tk/ganciclovir combination gene therapy A Pacholska, T Wirth, H Samaranayake, J Pikkarainen, F Ahmad and S Ylä-Herttuala Cancer Gene Ther 2012 19: 870-874; advance online publication, October 19, 2012; 10.1038/cgt.2012.76 Abstract | Full Text Suppression of hepatocarcinoma model in vitro and in vivo by ECRG2 delivery using adenoviral vector H Song, C Song, H Wang, C Li, F Yang, S-H Lu, C Lin, Q Zhan, X Wang and H Qian Cancer Gene Ther 2012 19: 875-879; advance online publication, October 19, 2012; 10.1038/cgt.2012.77 Abstract | Full Text CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC T Nguyen-Hoai, O Hohn, M D Vu, G Baldenhofer, M S Sayed Ahmed, B Dörken, S Norley, M Lipp, A Pezzutto and J Westermann Cancer Gene Ther 2012 19: 880-887; advance online publication, October 26, 2012; 10.1038/cgt.2012.78 Abstract | Full Text HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice S H MacLeod, M M Elgadi, G Bossi, U Sankar, A Pisio, K Agopsowicz, D Sharon, F L Graham and M M Hitt Cancer Gene Ther 2012 19: 888-898; advance online publication, October 26, 2012; 10.1038/cgt.2012.79 Abstract | Full Text Advertisement Ensure your access If you are unable to access the articles in this Table of Contents e-alert, your library may not subscribe to this journal. Our online recommendation form is a simple way to make your librarian aware that this journal is valuable to your research. Recommend now.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Cancer Gene Therapy. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.